Citadel Advisors
GH icon

Citadel Advisors’s Guardant Health GH Stock Holding History

Citadel Advisors’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71.7M Buy
775,941
+211,599
+37% +$21.2M 0.01% 1059
2025
Q4 		$57.6M Buy
564,342
+259,822
+85% +$23.2M 0.01% 1288
2025
Q3 		$19M Sell
304,520
-2,634,033
-90% -$143M ﹤0.01% 2405
2025
Q2 		$153M Sell
2,938,553
-658,360
-18% -$29.4M 0.03% 515
2025
Q1 		$153M Buy
3,596,913
+2,115,024
+143% +$91.2M 0.03% 477
2024
Q4 		$45.3M Buy
1,481,889
+1,151,488
+349% +$32.4M 0.01% 1361
2024
Q3 		$7.58M Sell
330,401
-2,960,496
-90% -$83.8M ﹤0.01% 3324
2024
Q2 		$95M Buy
3,290,897
+500,359
+18% +$11.7M 0.02% 711
2024
Q1 		$57.6M Buy
2,790,538
+2,762,668
+9,913% +$59.2M 0.01% 1096
2023
Q4 		$754K Sell
27,870
-410,445
-94% -$10.8M ﹤0.01% 7243
2023
Q3 		$13M Buy
438,315
+28,418
+7% +$999K ﹤0.01% 2358
2023
Q2 		$14.7M Buy
409,897
+142,831
+53% +$4.1M ﹤0.01% 2206
2023
Q1 		$6.26M Sell
267,066
-16,572
-6% -$473K ﹤0.01% 3449
2022
Q4 		$7.71M Sell
283,638
-68,214
-19% -$3.12M ﹤0.01% 3177
2022
Q3 		$18.9M Buy
351,852
+216,050
+159% +$11.1M ﹤0.01% 1929
2022
Q2 		$5.48M Sell
135,802
-398,623
-75% -$19.8M ﹤0.01% 3624
2022
Q1 		$35.4M Buy
534,425
+14,669
+3% +$1M 0.01% 1394
2021
Q4 		$52M Buy
+519,756
New +$53.8M 0.01% 1135
2021
Q3 		– Sell
-166,664
Closed -$19.8M – 14088
2021
Q2 		$20.7M Sell
166,664
-79,867
-32% -$10.7M ﹤0.01% 2033
2021
Q1 		$37.6M Sell
246,531
-38,356
-13% -$5.8M 0.01% 1296
2020
Q4 		$36.7M Buy
284,887
+44,351
+18% +$5.1M 0.01% 1215
2020
Q3 		$26.9M Buy
240,536
+178,206
+286% +$16.3M 0.01% 1324
2020
Q2 		$5.06M Sell
62,330
-64,367
-51% -$5.19M ﹤0.01% 3069
2020
Q1 		$8.82M Buy
126,697
+81,876
+183% +$6.28M ﹤0.01% 2008
2019
Q4 		$3.5M Sell
44,821
-78,024
-64% -$5.62M ﹤0.01% 3572
2019
Q3 		$7.84M Buy
122,845
+45,771
+59% +$4.03M ﹤0.01% 2520
2019
Q2 		$6.65M Sell
77,074
-15,348
-17% -$1.17M ﹤0.01% 2698
2019
Q1 		$7.09M Buy
+92,422
New +$5.12M ﹤0.01% 2499

Other funds holding GH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's GH Position: Q1 2026 in Review

Citadel Advisors increased its Guardant Health (GH) stake by 37% in Q1 2026, buying an estimated $21.2M and bringing the position to 775,941 shares worth $71.7M. The position accounts for 0.01% of the portfolio, ranked #1059.

Citadel Advisors first reported a position in GH in Q1 2019 and has held it in 28 quarters since. The position peaked at $153M in Q1 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • Citadel Advisors held 775,941 shares of Guardant Health worth $71.7M as of Q1 2026.
  • Citadel Advisors bought 211,599 Guardant Health shares in Q1 2026, an estimated $21.2M.
  • Guardant Health made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1059 holding.
  • Citadel Advisors first reported a position in Guardant Health in Q1 2019 and has held it in 28 quarters since.
  • Citadel Advisors's Guardant Health position peaked at $153M in Q1 2025.
  • 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.